Non-Small Cell Lung Cancer (Stage III) Clinical Trials

11 recruiting

Frequently Asked Questions

Common questions about Non-Small Cell Lung Cancer (Stage III) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

HEARTS Trial for Thoracic Cancers

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-IIIEsophagogastric Cancer Stage I-III+2 more
University of Wisconsin, Madison60 enrolled1 locationNCT07132918
Recruiting
Phase 2

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Lung CancerNon-small Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+1 more
Case Comprehensive Cancer Center85 enrolled1 locationNCT07104630
Recruiting
Phase 2

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Non-Small Cell Lung Cancer (Stage III)
Georgetown University21 enrolled3 locationsNCT06449313
Recruiting
Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)Non-small Cell Lung Cancer Stage I+1 more
Stanford University80 enrolled1 locationNCT04585477
Recruiting

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

PDL1 Gene MutationNon-Small Cell Lung Cancer (Stage III)
Fundación GECP50 enrolled22 locationsNCT06634199
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled16 locationsNCT06463665
Recruiting
Phase 2

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Non-Small Cell Lung Cancer (Stage III)KRAS P.G12C
Fundación GECP19 enrolled20 locationsNCT05398094
Recruiting
Phase 4

Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab

Non-Small Cell Lung Cancer (Stage III)
Idris Bahce38 enrolled1 locationNCT06908070
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticSmall Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+3 more
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting
Not Applicable

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Non-Small Cell Lung Cancer (Stage III)
Ruijin Hospital56 enrolled1 locationNCT05557552
Recruiting
Phase 2

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer (Stage III)
Shanghai Pulmonary Hospital, Shanghai, China100 enrolled1 locationNCT04728724